Treatment Efficacy and Safety of TDF-TAF Switch Study in South Korea

• Conditions: Chronic Hepatitis b

• Registration Number: NCT03559790
• Lead Sponsor: The Catholic University of Korea

Brief Summary

Recent TAF has introduced to have more safe profiles than TDF in clinical trials. Especially, TDF has the renal safety issue in high risk group including HIV, decompensated cirrhosis (ascites), uncontrolled DM etc.

However, there is no available cohort data for treatment efficacy and safety in TDF-TAF switch therapy in treatment-naïve chronic hepatitis B.

The aim of this study is to evaluate safety and efficacy of TAF switch therapy in patients with chronic hepatitis B who have been treated with TDF.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-05-14
• Study First Submitted QC: 2018-06-14
• Study First Posted: 2018-06-18
• Study Start: 2018-07-18
• Status Verified: 2019-01
• Last Update Submitted: 2019-01-29
• Last Update Posted: 2019-01-30
• Primary Completion: 2020-08
• Study Completion: 2021-08

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

1. Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures.

2. Adult male and non-pregnant, non-lactating female subjects, 18 years of age and older, based on the date of the screening visit. A negative serum pregnancy test at Screening is required for female subjects of childbearing potential (unless surgically sterile or greater than 2 years post-menopausal).

3. Documented evidence of chronic HBV infection (e.g. HBsAg positive for more than 6 months)

4. Previous TDF naïve treatment (more than 96 weeks) baseline status including chronic hepatitis B with the following:

   • HBeAg-positive and HBeAb negative at Screening

   • Screening HBV DNA ≥ 1x 105 copies/mL

   • Screening serum ALT level ≥2×ULN(80 IU/L) and ≤ 10 ×ULN (by center laboratory range) OR

   • HBeAg-negative and HBeAb positive at Screening

   • Screening HBV DNA ≥ 1x 104 copies/mL

   • Screening serum ALT level ≥2×ULN(80 IU/L) and ≤ 10 ×ULN (by center laboratory range) OR

   • Cirrhosis at Screening

   • Screening HBV DNA ≥ 1x 104 copies/mL regardless of HBeAg status

     • Treatment naïve subjects defined as no history of antiviral therapy or < 12 weeks of oral antiviral treatment with any nucleoside or nucleotide analogue, including lamivudine or adefovir, clevudine, telbivudine, entecavir

5. The decision is made by the provider and patient to switch from TDF to TAF prior to discussion of the study of enrollment

6. Following the decision to switch therapy, signed written informed consent after being instructed about the objective and procedure of the clinical study

7. Must be willing and able to comply with all study requirements

Exclusion Criteria

Subjects who meet any of the following exclusion criteria are not to be enrolled in the study.

1. Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study.
2. Co-infection with HCV, HIV
3. Evidence of hepatocellular carcinoma (e.g. α-fetoprotein> 50 ng/mL or as evidenced by recent ultrasound or other standard of care measure)
4. Malignancy within 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (basal cell skin cancer, etc). Subjects under evaluation for possible malignancy are not eligible
5. Current alcohol or substance abuse judged by the investigator to potentially interfere with subject compliance
6. Currently receiving therapy with cytotoxic agent, nephrotoxic agents, or agents capable of modifying renal excretion
7. Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with dosing requirements.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Complete Virological response	at Week 96.	Portion of subjects with plasma HBV DNA levels below 116 copies/mL
Incidence of of elevation of serum creatinine as a measure of renal safety	at Week 96	Incidence of elevation of serum creatinine (\>0.5mg/dL) from baseline creatinine
Incidence of osteopenia and osteoporosis as a measure of bone safety	at Week 96	Incidence of osteopenia and osteoporosis according to Bone Mineral Density

Secondary Outcome Measures

Name	Time	Method
Biochemical response	at Week 48 and 96	ALT normalization (Male \<30 IU/L, Female \<19 IU/L)
Serologic response	at Week 48 and 96	seroconversion rate in HBeAg positive patients
Incidence of treatment-emergent adverse events	at Week 48 and 96	all adverse events during tenofovir treatment

Trial Locations

Locations (1)

The Catholic University of Korea, Daejeon St.Mary's Hosptial; 🇰🇷 Junggu, Daejeon, Korea, Republic of